Professor Paul Fitzgerald is an academic psychiatrist expert in experimental studies and clinical trials for development of novel treatment options for patients with depression, schizophrenia, OCD, PTSD, autism and Alzheimer’s disease. He is a global authority in repetitive transcranial magnetic stimulation (rTMS).

He’s had continual NHMRC grant support for 20 years and $10+ million in research support in the last five years. He established multiple clinical rTMS services, founded device and clinical service companies and led a national application to MSAC which resulted, in 2021, in Medicare funding ($280 million in year 1) for rTMS therapy for patients with depression.